Compare MEG & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | ORIC |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 943.9M | 783.0M |
| IPO Year | 2020 | 2020 |
| Metric | MEG | ORIC |
|---|---|---|
| Price | $24.71 | $8.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $33.50 | $19.50 |
| AVG Volume (30 Days) | 338.1K | ★ 1.4M |
| Earning Date | 11-04-2025 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $826,323,000.00 | N/A |
| Revenue This Year | $19.70 | N/A |
| Revenue Next Year | $2.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.77 | N/A |
| 52 Week Low | $10.51 | $3.90 |
| 52 Week High | $32.00 | $14.93 |
| Indicator | MEG | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 28.73 |
| Support Level | $25.63 | $7.96 |
| Resistance Level | $26.43 | $8.44 |
| Average True Range (ATR) | 0.95 | 0.43 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 0.68 | 11.01 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.